New advances of taxol in clinical application of breast cancer
- VernacularTitle:紫杉醇在乳腺癌化疗临床应用的新进展
- Author:
Zefei JIANG
;
Santai SONG
- Publication Type:Journal Article
- Keywords:
breast neoplasms;
chemotherapy;
paclitaxel
- From:China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Taxol is one of the most active agent in metastatic breast cancer. Taxol is also an excellent choice for combination therapy by its unique mechanism of action and favorable toxicity profile. Numerous phase II clinical studies have combined taxol with other active agents such as the anthracyclines, gemcitabine, carboplatin and Herceptin. In the adjuvant chemotherapy for early stage breast cancer, two large international clinical trials demonstrated the role of taxol in early breast cancer. CALGB 9344 demonstrated the addition of four cycles of taxol after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer. CALGB 9741 showed dose density chemotherapy of taxol improves clinical outcomes significantly, while sequential chemotherapy is as effective as concurrent chemotherapty.
